

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

#6
Harry
Dec. 23, 2000

Application of: Robert J. SCHNEIDER *et al.*

Application No.: 09/305,084

Filed: May 4, 1999

For: CANCER TREATMENT WITH
ENDOTHELIN RECEPTOR
ANTAGONISTS



Group Art Unit: 1642

Examiner: Alana M. Harris

Attorney Docket No.: 5914-080-999

RECEIVED

DEC 14 2000

TECH CENTER 1600/2900

**REQUEST FOR RECONSIDERATION OF RESTRICTION REQUIREMENT WITH
PROVISIONAL ELECTION UNDER 37 C.F.R. §1.143**

Assistant Commissioner for Patents
Office of Initial Patent Examination
Customer Service Center
Washington, D.C. 20231

Sir:

In response to the Restriction Requirement dated November 17, 2000, and in accordance with Rule 142 of the Rules of Practice, please consider the following remarks.

Applicant submits herewith: (a) a copy of the pending claims, attached hereto as Exhibit A.

It is not believed that extensions of time or fees for net addition of claims are required beyond those that may otherwise be provided for in documents accompanying this paper. However, if additional extensions of time are necessary to prevent abandonment of this application, then such extensions of time are hereby petitioned under 37 C.F.R.

§ 1.136(a), and any fees required therefor (including fees for net addition of claims) are hereby authorized to be charged to PENNIE & EDMONDS LLP Deposit Account No. 16-1150.